“`html
The average one-year price target for Relmada Therapeutics (NasdaqCM:RLMD) has been revised to $10.20 per share, reflecting a 900.00% increase from the previous estimate of $1.02 on November 14, 2025. This new target varies among analysts, ranging from a low of $10.10 to a high of $10.50, representing an increase of 140.57% from the last reported closing price of $4.24 per share.
As of the last quarter, 53 funds or institutions report positions in Relmada Therapeutics, a decrease of 5 owners or 8.62%. Institutional ownership increased by 47.26% to 8,393,000 shares. The put/call ratio stands at 0.02, indicating a bullish outlook for the stock.
Notable ownership changes include Ikarian Capital, which increased its stake by 97.82% to 1,843,000 shares, and Boothbay Fund Management, which reported a 100% increase to 693,000 shares. Driehaus Capital Management maintains its 740,000 shares, while Acadian Asset Management reduced its holding to 583,000 shares but increased its allocation substantially by 166.64% over the last quarter.
“`
